Interleukin Genetics,Inc. (OTCMKTS:ILIU) Files An 8-K Results of Operations and Financial ConditionItem 9.01
The information set forth in Item 9.01 is hereby incorporated by reference into this Item 9.01.
| Item 9.01 | Costs Associated with Exit or Disposal Activities. |
The information set forth in Item 9.01 is hereby incorporated by reference into this Item 9.01.
On July 3, 2017, Interleukin Genetics, Inc. (the “Company”) issued a press release announcing that is seeking strategic alternatives and restructuring its operations.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
The following exhibit is filed with this report:
| Exhibit Number | Description |
| 99.1 | Press Release dated July 3, 2017. |
INTERLEUKIN GENETICS INC ExhibitEX-99.1 2 v470233_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Interleukin Genetics To Explore Strategic Alternatives,…To view the full exhibit click here
About Interleukin Genetics,Inc. (OTCMKTS:ILIU)
Interleukin Genetics, Inc. develops and markets genetic tests for chronic diseases and health-related conditions. The Company operates through the genetic test business segment. The Company’s products include PerioPredict genetic test and Inherent Health line of genetic tests. PerioPredict is a genetic risk test that analyzes genetic variations associated with inflammation and identifies individuals with a life-long predisposition to over-produce inflammation. PerioPredict identifies specific polymorphisms (genetic variations) in genes that regulate the production of interleukin-1 cytokines. PerioPredict identifies adults at increased risk for severe periodontal disease. The Company markets additional genetic tests through its Inherent Heath brand. Its additional genetic tests include weight management genetic test, bone health genetic test, heart health genetic test, nutritional needs genetic test and wellness select genetic test.
